AzTrials
AzTrials

Diagnostic Coronary AngiographyPhase 3NCT01260519

Effect of Heparin on Femoral Arterial Sheaths Thrombosis During Diagnostic Coronary Angiography

A Phase 3 study testing Heparin in people with Diagnostic Coronary Angiography, run by Prince Sultan Cardiac Center, Adult Cardiology Department. at 1 site in Saudi Arabia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The project tests the incidence of femoral arterial sheath thrombus formation during diagnostic coronary angiography and effect of intravenous (iv) heparin bolus administration in reducing this risk in comparison to placebo. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Diagnostic Coronary Angiography
What is being tested?
Heparin
Could I receive a placebo?
No, everyone receives an active treatment
How many people
304 participants
Where
1 siteSaudi Arabia
Study dates
Jul 2008to Oct 2010
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Included all adult patients undergoing cardiac catheterization

Who cannot join

  • Contraindication to heparin
  • Platelet count <100,000/mm3
  • Patient with bleeding diathesis or hypercoagulable state.
  • Use of chronic anticoagulation with INR > 1.4
  • Patient refusal or inability to follow the protocol

Trial locations and contacts

1 site in 1 country.

Saudi Arabia1 site
  • Prince Sultan Cardiac Center

    Riyadh, Central, 11159

Other trials in Saudi Arabia

About this study

Official title: Efficacy of a Single Dose Intravenous Heparin During Diagnostic Angiography in Reducing Sheath-clot Formation: A Randomized Controlled Trial

The project tests the incidence of femoral arterial sheath thrombus formation during diagnostic coronary angiography and effect of intravenous (iv) heparin bolus administration in reducing this risk in comparison to placebo.

Read the detailed description

PURPOSE:

The purpose of this study was to evaluate the incidence of blood clots in femoral arterial sheaths during coronary angiographic procedures and the effect of heparin administration on thrombus formation.

BACKGROUND:

A heparinized saline flushes are used during diagnostic coronary angiography to prevent thrombus formation within the lumen of the sheath. However, the use of prophylactic intravenous heparin following the femoral arterial sheath insertion is controversial. The aim of this study was to evaluate the effectiveness of 2000 units heparin intravenous bolus versus saline placebo on thrombus formation within arterial sheath during the diagnostic coronary angiography.

Methods A randomized controlled trial to examine the efficacy of intravenous heparin bolus compared with placebo in prevention of femoral arterial sheath thrombus formation in patients undergoing diagnostic coronary angiography.

The study included all adult patients undergoing cardiac catheterization. Eligible patients were recruited from day-case and in-patients wards of the Prince Sultan Cardiac Centre (PSCC), Riyadh. Patients with abnormal coagulation profile, abnormal platelet count and those receiving enoxaparin, or glycoprotein IIb/IIa antagonists were excluded.

Since the coronary interventions require anticoagulation during the procedure, our study was interested in the diagnostic part. After insertion of femoral arterial sheath one group was allocated to 2 milliliter solution containing 2000 units of heparin and the other group to similar amount of placebo solution which is blinded to both patient and operating catheterization laboratory staff. Arterial access was obtained via femoral approach and 6F to 7F Sheaths were used. The femoral sheath was aspirated and flushed for presence of thrombi or obstruction after each catheter exchange and at the end of the procedure. Two steps aspiration was performed where 5 cc of blood were extracted in one syringe then another saline filled syringe was used for flushing. We used clean white gauze to look for presence of thrombi, and if thrombi were noticed further aspiration was performed followed by saline flush. Any visible thrombus at any stage of the procedure was considered positive. The patients evaluated and assessed clinically during hospital stay for presence of leg ischemia, Femoral and Pedal pulses, Local hematoma or bleeding.

All patients gave informed consent, and the study protocol was approved by the PSCC Ethics Committee.

Randomization Patients were randomized based catheterization laboratory flow, where the first laboratory assigned to treatment number one and the second laboratory assigned to treatment number two on alternate days, sealed and labeled syringes that contained the treatment allocation came from pharmacy on daily basis and handled to an independent laboratory staff nurse assigned to maintain concealed to patients and healthcare providers Throughout the study. The labels were uncovered opened only after the femoral puncture and arterial sheath insertion confirmed and the patient had provided written informed consent to participate in the study. Once the seal was broken, the patient was considered irrevocably randomized.

Study Interventions Patients were randomized to receive either heparin or placebo. Patients in the heparin group received 2000 units (2 ml) of unfractionated heparin intravenous bolus. Those randomized to the placebo received 2ml of saline based solution intravenous bolus.

The femoral sheath was aspirated and flushed for presence of thrombi or obstruction after each catheter exchange and at the end of the procedure. Two steps aspiration was performed where 5 cc of blood were extracted in one syringe then another saline filled syringe was used for flushing. We used clean white gauze to look for presence of thrombi, and if thrombi were noticed further aspiration was performed followed by saline flush. Any visible thrombus at any stage of the procedure was considered positive. The patients evaluated and assessed clinically during hospital stay for presence of leg ischemia, Femoral and Pedal pulses, Local hematoma or bleeding.

Outcomes The primary end point was the occurrence of arterial sheath thrombi, defined as Any visible thrombus during sheath blood aspiration at any stage of the procedure. The second primary end point was efficacy of intravenous heparin bolus in reducing the risk of thrombus formation.

Patients were monitored for embolic and bleeding events until they were discharged from the hospital. Embolic events defined as appearance of symptoms and signs of acute limb ischemia like acute leg pain and loss of pedal pulses that result in interventional or surgical exploration. Bleeding events was defined as local femoral access bleeding or hematoma that led to surgical exploration.

The diagnosis of embolization or hematoma was made clinically (loss of arterial pulse or evidence of leg ischemia) and confirmed by Doppler studies when appropriate.

Outcomes were assessed by the patients' treating physicians, who were aware of treatment assignment.

Being tested
Heparin

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • HeparinDrug

    Also called unfractionated heparin

    unfractionated heparin 2000 unites

Study groups in NCT01260519
Study groupRoleWhat they receive
active arm: heparinExperimentalNot described
Receives: Drug: Heparin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The incidence of femoral arterial sheath thrombi and the efficacy of heparin bolus in preventing sheath thrombosis

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Dec 2010 (estimated)
  2. Study startJul 2008
  3. Primary completionOct 2010
  4. Study completionOct 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
304 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01260519
Sponsor's protocol ID
PSCC-00001- HT
Status last verified
Dec 2010
First submitted
19 Nov 2010
Last updated
15 Dec 2010
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Heparin in people with Diagnostic Coronary Angiography, run by Prince Sultan Cardiac Center, Adult Cardiology Department. at 1 site in Saudi Arabia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Dec 2010. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Saudi Arabia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The incidence of femoral arterial sheath thrombi and the efficacy of heparin bolus in preventing sheath thrombosis. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2010.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in